Vast DemandWide moat

Eli Lilly (LLY) — moat facet

A market limited by manufacturing capacity, not by customers.

The incretin drugs — the GLP-1 class that includes Lilly's tirzepatide — have opened a market whose defining feature is almost unheard-of: demand so vast that the binding constraint has been supply, not customers. Obesity and diabetes affect hundreds of millions of people worldwide, and for the first time medicine offers treatments that produce dramatic, reliable weight loss and metabolic improvement. The addressable population is a large fraction of humanity, and the drugs work well enough that demand has overwhelmed the industry's ability to make them.

Tirzepatide revenue, U.S. and abroad ($M)$6,682MU.S. Q2 25$9,664MU.S. Q2 26$1,899MEx-U.S. Q2 25$5,207MEx-U.S. Q2 26Lilly Form 10-Q, June 2026
Demand outside America nearly tripled in a year.

The scale is what makes this a generational opportunity rather than merely a good drug. Where most blockbusters serve a defined patient population, the incretins address conditions so widespread that the market could run to hundreds of billions of dollars a year, and the medical case keeps broadening as the drugs show benefits beyond weight — for heart failure, sleep apnea, kidney disease, and more. Lilly's Mounjaro and Zepbound generated $36.5 billion combined in 2025 and $27.7 billion in the first half of 2026 alone,123 growing at extraordinary rates, and the market is nowhere near saturated.

The demand is real and durable, but not without qualifications. Access depends heavily on insurance coverage and price, which are contested; supply, though improving, has been a genuine constraint; and a market this large and profitable attracts ferocious competition and, eventually, cheaper alternatives. Still, the sheer size of the incretin opportunity — a market limited by how fast the drugs can be made rather than by how many people want them — is the single most powerful force behind Lilly's rise, and a tailwind few companies in any industry ever enjoy.

Moat trajectory: Widening

Widening. The incretin market keeps getting larger, not smaller, as the drugs prove benefits beyond weight — in heart failure, sleep apnea, kidney disease — each new indication expanding the population that will take them for years. What began as a diabetes drug is becoming a broad metabolic-health medicine for a huge fraction of humanity. Gated by coverage and price, and eventually by competition, but the underlying addressable market is genuinely expanding. A rare and widening tailwind.

The number that tests this moat
Moat Explorer calc
Tirzepatide revenue outside the U.S., latest quarter
$5.2B in Q2 2026, from $1.9B

Demand beyond America is the newest pool: outside-U.S. volume rose 113% in the quarter while price fell 36%.

How it's calculated: Mounjaro 5,152 + Zepbound 55 = 5,207; 1,897 + 2 = 1,899.
Source: Lilly Form 10-Q, quarter ended 30 June 2026 ↗
⚠ Threats to the moat
⚠ THREAT 01
Coverage and Cost Gate the Demand
Vast demand becomes revenue only where an insurer agrees to pay.
References
  1. ReportedLilly's Mounjaro and Zepbound generated $36.5 billion combined in 2025 and $27.7 billion in the first half of 2026 alone, growing at extraordinary rates, and the market is nowhere near saturated.
    Eli Lilly Form 10-K, FY2025 - revenue $65,179M (Mounjaro $22,965M, Zepbound $13,542M, Verzenio $5,723M); gross margin 83.0% (81.3%); R&D $13,337M; marketing, selling and administrative $11,094M; acquired IPR&D $2,910M; net income $20,640M; price -6% and volume +50% (U.S. price -10%, volume +53%); rebates, discounts and returns deducted $62,135M; capital expenditure $7,841M; operating cash flow $16,813M ($8,818M, $4,240M); U.S. compound patents: Cyramza 2026, Trulicity 2027, Jardiance 2029, Verzenio 2031, Olumiant 2032, Mounjaro/Zepbound 2036, Jaypirca 2037, Retevmo 2038, Inluriyo 2039; HHS selected Trulicity and Verzenio in January 2026 for government-set prices effective 2028; six products above $3 billion were 82% of revenue; three wholesalers each 16%-24% of revenue — FY2023-FY2025 · publ. February 2026 · source ↗
  2. ReportedLilly's Mounjaro and Zepbound generated $36.5 billion combined in 2025 and $27.7 billion in the first half of 2026 alone, growing at extraordinary rates, and the market is nowhere near saturated.
    Eli Lilly Form 10-Q, quarter ended 30 June 2026 - revenue $22,974M (+48%): Mounjaro $9,943M (U.S. $4,791M, outside $5,152M), Zepbound $4,928M, Jardiance $1,232M, Trulicity $1,219M, Verzenio $1,474M; oncology $2,570M, immunology $1,417M, neuroscience $429M; volume +60% and price -13% (U.S. +37%/-3%, outside +113%/-36%); gross margin 85.8% (84.3%); R&D $3,819M; MS&A $3,430M; acquired IPR&D $2,776M; special charges $703M; tax rate 23.3% (16.5%); net income $7,095M; diluted EPS $7.94; H1 capital expenditure $5,259M and operating cash flow $16,023M — Q2 2026 · publ. August 2026 · source ↗
  3. Moat Explorer calcLilly's Mounjaro and Zepbound generated $36.5 billion combined in 2025 and $27.7 billion in the first half of 2026 alone, growing at extraordinary rates, and the market is nowhere near saturated.
    Moat Explorer calculation from Lilly's Forms 10-K FY2021-FY2025 and the Q2 2026 10-Q: tirzepatide (Mounjaro + Zepbound) $36,507M in 2025, $14,871M in Q2 2026 ($8,580M), trailing twelve months $49,466M; trailing revenue $79,666M; margins and shares as stated — 2021 to Q2 2026 · publ. 2026-09-23 · source ↗
Sources
Generated September 23, 2026